Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion

NCT ID: NCT00978900

Last Updated: 2009-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Artificial Sweeteners significantly lower energy density of foods and beverages. They are used by diabetics as sugar substitutes as well as by consumers as aids for dietary control. Despite numerous studies which show mainly no influence of artificial sweeteners on glucose metabolism and food intake, discrepancies consist about the real effects of artificial sweeteners. Studies by Blundell and Hill in 1986 have however shown that the consumption of artificial sweeteners resulted in an increase of appetite ratings; the efficiency of AS has therefore been questioned. With respect to the world wide increase in the prevalence in obesity, it seems important to clarify whether artificial sweeteners can help regulate body weight or not. This study will explore the effect of artificial sweeteners on the release of the gastrointestinal satiety hormones PYY, GLP-1, GIP and ghrelin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acesulfame K

Group Type ACTIVE_COMPARATOR

Artificial sweeteners; Carbohydrate Sugars

Intervention Type DIETARY_SUPPLEMENT

sweetening agent dissolved in tap water, administered via intragastric tube

Sucralose

Group Type ACTIVE_COMPARATOR

Artificial sweeteners; Carbohydrate Sugars

Intervention Type DIETARY_SUPPLEMENT

sweetening agent dissolved in tap water, administered via intragastric tube

Aspartame

Group Type ACTIVE_COMPARATOR

Artificial sweeteners; Carbohydrate Sugars

Intervention Type DIETARY_SUPPLEMENT

sweetening agent dissolved in tap water, administered via intragastric tube

Glucose

Group Type ACTIVE_COMPARATOR

Artificial sweeteners; Carbohydrate Sugars

Intervention Type DIETARY_SUPPLEMENT

sweetening agent dissolved in tap water, administered via intragastric tube

Fructose

Group Type ACTIVE_COMPARATOR

Artificial sweeteners; Carbohydrate Sugars

Intervention Type DIETARY_SUPPLEMENT

sweetening agent dissolved in tap water, administered via intragastric tube

Water

Group Type PLACEBO_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artificial sweeteners; Carbohydrate Sugars

sweetening agent dissolved in tap water, administered via intragastric tube

Intervention Type DIETARY_SUPPLEMENT

Water

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subject with a body-mass index of 19.0-24.5
* Normal eating habits
* Age 18-40 years
* Stable body weight for at least three months

Exclusion Criteria

* Smoking
* Substance abuse
* Regular intake of medications (except for oral contraceptives)
* Medical or psychiatric illness
* history of gastrointestinal disorders
* food allergies
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Gastroenterology, University Hospital, Basel, Switzerland

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Beglinger, MD

Role: PRINCIPAL_INVESTIGATOR

Clinical Research Center, University Hospital Basel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EKBB 69/04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.